Azithral 500mg (Azithromycin) – Saskatoon, Saskatchewan, Canada (2026)
Visit
Website: unnatipharmax.com
Phone: +91 82650 41513
Email: Unnatipharmax@gmail.com
PRODUCT NAME
Brand Name: Azithral 500mg
Generic Name: Azithromycin 500 mg
Strength: 500 mg
Dosage Form: Tablets
Therapeutic Category: Macrolide Antibiotic
PRODUCT DETAILS
Azithral 500mg contains Azithromycin 500 mg, a macrolide antibiotic indicated for the treatment of susceptible bacterial infections. It works by inhibiting bacterial protein synthesis, helping stop the growth of susceptible bacteria. This medicine should only be used under the guidance of a qualified healthcare professional and is not effective against viral illnesses such as the common cold or influenza.
It may be prescribed for susceptible bacterial infections including:
- Community-acquired respiratory tract infections
- Certain ear, nose, and throat bacterial infections
- Skin and soft tissue infections
- Certain sexually transmitted bacterial infections when clinically indicated
- Other susceptible bacterial infections as determined by a healthcare professional
PRODUCT SPECIFICATION
| Specification | Details |
|---|---|
| Brand Name | Azithral 500mg |
| Generic Name | Azithromycin |
| Strength | 500 mg |
| Dosage Form | Tablet |
| Route | Oral |
| Therapeutic Class | Macrolide Antibiotic |
| Packaging | Blister Pack |
| Storage | Store below 25°C in a cool, dry place |
| Prescription | Required |
| Manufactured In | India |
| Export Availability | Worldwide (where legally permitted) |
KEY FEATURES
- Contains Azithromycin 500 mg
- Macrolide antibiotic for susceptible bacterial infections
- Oral tablet formulation
- Manufactured in WHO-GMP compliant facilities
- Quality-assured pharmaceutical product
- Secure packaging for international export
- Available for retail, wholesale, and bulk supply
- Competitive export pricing
- Worldwide shipping where legally permitted
- Intended for use under medical supervision
INDUSTRY UPDATE (2026)
The global antibiotics market continues to emphasize appropriate antibiotic use and antimicrobial stewardship to help preserve treatment effectiveness and reduce antimicrobial resistance (AMR). Macrolide antibiotics such as Azithromycin remain widely used for selected bacterial infections when prescribed according to clinical guidelines.
Key industry trends in 2026 include:
- Increased focus on responsible antibiotic prescribing
- Greater adoption of rapid diagnostic testing for targeted therapy
- Continued surveillance of global antimicrobial resistance patterns
- Growing demand for high-quality generic antibiotics in international markets
- Ongoing investment in pharmaceutical manufacturing quality, regulatory compliance, and reliable global medicine supply chains
Saskatoon's Royal University Hospital and the Saskatoon Health Region manage bacterial infections for Saskatchewan's agricultural heartland city — including its significant Indigenous community with elevated respiratory infection burden, the growing South Asian professional community, and Saskatoon's extensive farming community. Saskatchewan's harsh subarctic climate creates intense respiratory infection seasons where Azithral 500mg is a cornerstone treatment. Azithral 500mg provides Saskatoon residents with affordable Azithromycin at dramatically reduced cost versus Saskatchewan pharmacy pricing.
Visit unnatipharmax.com | 📱 +91 82650 41513 | 📧 Unnatipharmax@gmail.com
FAQ 1: How does Saskatoon's extreme subarctic winter create one of Canada's highest respiratory infection burdens?
Saskatoon's January average of -16°C (with wind chills to -40 to -50°C) creates respiratory infection conditions that rival the world's most extreme cold-weather disease environments. The cold-infection mechanism: extreme cold causes mucociliary dysfunction in the upper airways — the tiny cilia that sweep pathogens upward and outward from the respiratory tract are impaired by cold air (ciliary beat frequency decreases in cold temperatures); simultaneously, cold air desiccates the nasal mucosa, reducing the protective mucus layer that traps inhaled bacteria and viruses; and the extreme cold drives Saskatoon residents indoors into heated, densely occupied spaces (schools, churches, community centres, worker common areas) where respiratory pathogen transmission is amplified. Saskatoon's respiratory infection peak: November through March is the intense respiratory infection season; respiratory syncytial virus (RSV), influenza, and bacterial secondary pneumonia (particularly Streptococcal) peak in January-February when indoor congregation is most intense and mucociliary defences are most compromised. Azithral 500mg for Saskatoon's winter pneumonia: atypical pneumonia (Mycoplasma, Chlamydophila) is particularly prevalent in Saskatoon's younger working and student population during winter; Royal University Hospital's emergency department manages community-acquired pneumonia presentations peaking in February — Azithral 500mg as outpatient therapy for low-severity atypical CAP reduces the hospitalisation burden for RUH during its busiest winter infectious period. Saskatchewan Drug Plan covers Azithromycin for respiratory infection indications for eligible Saskatchewan residents; Azithral 500mg from Unnati Pharmax serves Saskatoon residents in SDP processing gaps and for those above SDP income threshold without adequate private drug coverage during Saskatoon's demanding winter infection season.
FAQ 2: How does Saskatoon's Indigenous community — with elevated respiratory infection burden — access Azithral 500mg?
Saskatoon's urban Indigenous community — concentrated in the core neighbourhoods of Pleasant Hill, Confederation Park, and Westmount — has the highest respiratory infection morbidity of any Saskatoon demographic group. Indigenous respiratory infection burden: Indigenous people in Saskatchewan experience pneumonia hospitalisation rates 3-4 times higher than the provincial average — driven by housing overcrowding (a persistent challenge in Saskatoon's urban Indigenous community despite housing programme efforts), elevated smoking rates, higher rates of underlying COPD and asthma from historical wood-smoke exposure, and nutritional deficits from the poverty that disproportionately affects Saskatchewan's urban Indigenous population. COVID-19 long-term consequences: the COVID-19 pandemic disproportionately affected Saskatchewan's Indigenous community — higher rates of severe infection left a portion of Saskatoon's urban Indigenous population with post-COVID respiratory impairment that elevates subsequent bacterial pneumonia risk. Non-Insured Health Benefits (NIHB) coverage for Azithral: NIHB through Health Canada covers Azithromycin for eligible First Nations and Inuit patients in Saskatoon — NIHB is theoretically comprehensive for these infections; however, NIHB processing sometimes creates delays for first-time users or when the prescribing form hasn't been submitted. Saskatoon's Walk-In clinics: Saskatoon's numerous walk-in medical clinics (the primary access point for Saskatoon's Indigenous community when GP access is unavailable) prescribe Azithromycin for respiratory infections; many walk-in patients are directed to fill prescriptions at Saskatoon's pharmacy chains at full price when SDP or NIHB documentation isn't immediately available. Azithral 500mg from Unnati Pharmax at dramatically reduced cost addresses this specific gap for Saskatoon's Indigenous patients with valid prescriptions but coverage documentation delays.
FAQ 3: How does Azithral 500mg treat chlamydial STI in Saskatoon — one of Canada's highest-rate provincial capitals?
Saskatchewan consistently has Canada's highest chlamydia and gonorrhoea rates per capita — a public health challenge that Saskatoon's STI programme specifically targets. Saskatchewan's STI burden context: rural and remote communities with limited sexual health services; Indigenous populations with the highest STI rates in the province; and inadequate sexual health education in Saskatchewan's conservative provincial school curriculum. Azithral 500mg for chlamydia: Azithromycin 1g single dose (two 500mg tablets taken simultaneously) is the first-line treatment for uncomplicated genital chlamydia (Chlamydia trachomatis infection) — providing a one-time directly observed therapy option that eliminates adherence concerns in Saskatoon's high-risk population. Saskatchewan's STI programme distribution: the Saskatoon Community Clinic STI services and the Saskatchewan Health Authority's sexual health clinic provide STI testing and treatment — Azithromycin single dose for chlamydia is dispensed directly at these clinics for eligible patients. The Indigenous STI burden in Saskatoon: STI rates in Saskatoon's Indigenous community are 5-10 times higher than non-Indigenous provincial rates — the Saskatoon Community Clinic's culturally safe STI services (employing Indigenous health educators and navigators) provide the most trusted STI testing and treatment access for Saskatoon's urban Indigenous community. Partner treatment: Chlamydia treatment is most effective when both the diagnosed patient and their sexual partner(s) are treated simultaneously; Azithral 500mg from Unnati Pharmax enables partner-delivered antibiotic therapy (PDAT) when partners cannot access Saskatoon STI clinics promptly — using the clinical framework established by the SHA's sexual health programme where prescriptions are issued for partners.
FAQ 4: How does Saskatchewan Drug Plan cover Azithral 500mg and what are the access gaps in Saskatoon?
Saskatchewan's provincial drug plan (SDP) covers Azithromycin for eligible Saskatchewan residents under formulary coverage with standard dispensing fees. The SDP Azithral coverage pathway: Azithromycin is on Saskatchewan's formulary as a covered drug for respiratory and STI indications — prescriptions dispensed at Saskatoon's Shoppers Drug Mart, Pharmasave, and Safeway pharmacy locations are covered for SDP-enrolled patients at co-payment rates based on income. SDP coverage gaps in Saskatoon creating Azithral demand from Unnati Pharmax: the 3-month SDP new resident waiting period — newly arrived Saskatoon residents (growing South Asian professional community, temporary foreign workers in food processing, new university students from out of province) are not immediately SDP-eligible; Temporary Foreign Workers in Saskatoon's food processing and agricultural sector on Seasonal Agricultural Worker Programme (SAWP) work permits may not have comprehensive provincial drug plan access; and self-employed entrepreneurs and farm operators who haven't enrolled in SDP's voluntary coverage — particularly relevant in Saskatchewan's agricultural entrepreneur community. The Saskatoon STI clinic pathway: Saskatoon's publicly-funded STI clinics provide Azithromycin directly without pharmacy prescription for chlamydia treatment — this is the most accessible pathway for eligible Saskatoon residents; for those who cannot access the STI clinic (remote agricultural workers, those with transportation barriers to the Saskatoon clinic location), Azithral 500mg from Unnati Pharmax with valid prescription provides the affordable alternative. Cost comparison: standard Saskatoon pharmacy Azithromycin private cost $15-25 per course; Azithral 500mg from Unnati Pharmax at dramatically reduced cost — a meaningful saving for Saskatoon's agricultural workers and temporary residents on limited incomes.
FAQ 5: How does Azithral 500mg's unique pharmacokinetic profile — high tissue concentrations — benefit Saskatoon's infection management?
Azithromycin's pharmacokinetics are among the most distinctive of any antibiotic — creating specific clinical advantages that Royal University Hospital Saskatoon's infectious diseases team specifically leverages in treatment planning. The extended tissue concentration advantage: Azithromycin achieves tissue concentrations 10-100 times higher than plasma concentrations — driven by lysosomal accumulation (the drug concentrates in white blood cells, particularly macrophages and neutrophils) and distribution throughout most body tissues; this creates therapeutic concentrations in respiratory tract mucosa, lymph nodes, skin, and genitourinary tissues that far exceed plasma levels and persist for 5-7 days after the last dose. Clinical implications for Saskatoon: for Mycoplasma pneumoniae atypical pneumonia (a primary winter respiratory infection in Saskatoon's young population), Azithromycin's excellent lung tissue penetration means the 500mg daily for 3-5 days produces sustained lung tissue concentrations that continue for days after the last tablet; for Chlamydia trachomatis STI treatment, the macrophage concentration means Azithromycin reaches the intracellular location where Chlamydia replicates — intracellular pathogens that evade most antibiotics are accessible to Azithromycin's tissue-concentrating mechanism; for Saskatoon's cat scratch disease cases (Bartonella henselae — prevalent in Saskatoon's pet-owning households), Azithromycin's excellent intracellular tissue penetration achieves higher concentrations at the infection site than most alternatives. The once-daily dosing advantage for Saskatoon's agricultural workforce: the once-daily dosing regime of Azithral 500mg fits naturally into the morning routine of Saskatoon's farming community — unlike multiple-daily-dose antibiotics that conflict with fieldwork schedules; the 3-5 day total duration (versus 7-10 days for alternatives) also minimises treatment burden during Saskatoon's intense agricultural work seasons.
Website
Email Id
Contact Number
+91-8265041513
Azithral-500-mg-Azithromycin-Saskatoon
